S&P 500   4,472.64 (-0.23%)
DOW   34,755.82 (+0.12%)
QQQ   358.06 (-1.01%)
AAPL   164.70 (+0.12%)
MSFT   299.03 (-0.85%)
FB   312.09 (-1.41%)
GOOGL   2,669.01 (+0.11%)
AMZN   2,950.97 (-2.72%)
TSLA   970.50 (-2.59%)
NVDA   238.51 (-1.24%)
BABA   126.21 (-3.68%)
NIO   27.72 (-4.84%)
AMD   122.06 (+0.14%)
CGC   7.33 (-3.04%)
MU   84.11 (-1.13%)
GE   97.12 (-1.15%)
T   26.88 (-0.52%)
F   21.07 (-2.68%)
DIS   138.36 (-6.27%)
AMC   17.09 (-5.42%)
PFE   53.38 (-1.24%)
ACB   4.53 (-4.63%)
BA   208.27 (-2.76%)
S&P 500   4,472.64 (-0.23%)
DOW   34,755.82 (+0.12%)
QQQ   358.06 (-1.01%)
AAPL   164.70 (+0.12%)
MSFT   299.03 (-0.85%)
FB   312.09 (-1.41%)
GOOGL   2,669.01 (+0.11%)
AMZN   2,950.97 (-2.72%)
TSLA   970.50 (-2.59%)
NVDA   238.51 (-1.24%)
BABA   126.21 (-3.68%)
NIO   27.72 (-4.84%)
AMD   122.06 (+0.14%)
CGC   7.33 (-3.04%)
MU   84.11 (-1.13%)
GE   97.12 (-1.15%)
T   26.88 (-0.52%)
F   21.07 (-2.68%)
DIS   138.36 (-6.27%)
AMC   17.09 (-5.42%)
PFE   53.38 (-1.24%)
ACB   4.53 (-4.63%)
BA   208.27 (-2.76%)
S&P 500   4,472.64 (-0.23%)
DOW   34,755.82 (+0.12%)
QQQ   358.06 (-1.01%)
AAPL   164.70 (+0.12%)
MSFT   299.03 (-0.85%)
FB   312.09 (-1.41%)
GOOGL   2,669.01 (+0.11%)
AMZN   2,950.97 (-2.72%)
TSLA   970.50 (-2.59%)
NVDA   238.51 (-1.24%)
BABA   126.21 (-3.68%)
NIO   27.72 (-4.84%)
AMD   122.06 (+0.14%)
CGC   7.33 (-3.04%)
MU   84.11 (-1.13%)
GE   97.12 (-1.15%)
T   26.88 (-0.52%)
F   21.07 (-2.68%)
DIS   138.36 (-6.27%)
AMC   17.09 (-5.42%)
PFE   53.38 (-1.24%)
ACB   4.53 (-4.63%)
BA   208.27 (-2.76%)
S&P 500   4,472.64 (-0.23%)
DOW   34,755.82 (+0.12%)
QQQ   358.06 (-1.01%)
AAPL   164.70 (+0.12%)
MSFT   299.03 (-0.85%)
FB   312.09 (-1.41%)
GOOGL   2,669.01 (+0.11%)
AMZN   2,950.97 (-2.72%)
TSLA   970.50 (-2.59%)
NVDA   238.51 (-1.24%)
BABA   126.21 (-3.68%)
NIO   27.72 (-4.84%)
AMD   122.06 (+0.14%)
CGC   7.33 (-3.04%)
MU   84.11 (-1.13%)
GE   97.12 (-1.15%)
T   26.88 (-0.52%)
F   21.07 (-2.68%)
DIS   138.36 (-6.27%)
AMC   17.09 (-5.42%)
PFE   53.38 (-1.24%)
ACB   4.53 (-4.63%)
BA   208.27 (-2.76%)
NASDAQ:IMNM

Immunome News Headlines

$8.35
-0.40 (-4.57%)
(As of 01/21/2022 10:40 AM ET)
Add
Compare
Today's Range
$8.27
$8.74
50-Day Range
$8.75
$19.10
52-Week Range
$8.10
$63.78
Volume
431 shs
Average Volume
52,064 shs
Market Capitalization
$101.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-4.43
Get Immunome News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Immunome Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IMNM
News Sentiment

-0.22

0.34

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IMNM Articles
This Week

1

2

IMNM Articles
Average Week



Immunome (NASDAQ:IMNM) News Headlines Today

SourceHeadline
benzinga.com logoImmunome shares are trading lower after the company announced it received a clinical hold letter from the FDA in response to its recently submitted IND requesting further information. - Benzinga
benzinga.com - January 13 at 9:30 PM
benzinga.com logoThe Daily Biotech Pulse: Illumina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback - Benzinga
benzinga.com - January 13 at 4:30 PM
nasdaq.com logoHealth Care Sector Update for 01/11/2022: ILMN,ACCD,BDTX,IMNM - Nasdaq
nasdaq.com - January 11 at 9:16 PM
nasdaq.com logoHealth Care Sector Update for 01/11/2022: ACCD, BDTX, MNM - Nasdaq
nasdaq.com - January 11 at 3:59 PM
m.benzinga.com logoThe Daily Biotech Pulse: Illunina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback - Benzinga
m.benzinga.com - January 11 at 10:58 AM
bizjournals.com logoImmunome's stock drops following FDA setback for experimental Covid-19 'cocktail' - Philadelphia Business Journal - Philadelphia Business Journal
bizjournals.com - January 11 at 10:58 AM
finance.yahoo.com logoFDA Issues Clinical Hold On Immunome's COVID-19 Antibody Program
finance.yahoo.com - January 11 at 10:58 AM
MarketBeat logoImmunome (NASDAQ:IMNM) Price Target Lowered to $33.00 at Cantor Fitzgerald
americanbankingnews.com - January 11 at 9:26 AM
finance.yahoo.com logoImmunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19
finance.yahoo.com - January 10 at 7:53 PM
nasdaq.com logoBullish insiders at Immunome, Inc. (NASDAQ:IMNM) loaded up on US$628k of stock earlier this year - Nasdaq
nasdaq.com - December 17 at 1:25 PM
finance.yahoo.com logoBullish Immunome, Inc. (NASDAQ:IMNM) insiders filled their treasuries with US$628k worth of stock over last year
finance.yahoo.com - December 17 at 1:25 PM
finance.yahoo.com logoImmunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald - Yahoo Finance
finance.yahoo.com - December 7 at 12:34 PM
finance.yahoo.com logoImmunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald
finance.yahoo.com - December 7 at 12:34 PM
businesswire.com logoImmunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald - Business Wire
businesswire.com - December 7 at 7:34 AM
nasdaq.com logoWall Street Set To Open Significantly Higher - Nasdaq
nasdaq.com - December 1 at 5:23 PM
bizjournals.com logoImmunone expects its Covid-19 'cocktail' to neutralize the Omicron variant - Philadelphia Business Journal - Philadelphia Business Journal
bizjournals.com - December 1 at 5:23 PM
benzinga.com logoThe Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment, Regulatory Setbacks For CTI Biopharma, Favorable Ruling For BioXcel, Viatris In Tecfidera Patent Case - Benzinga
benzinga.com - December 1 at 12:23 PM
benzinga.com logoImmunome Announces Submission Of An Investigational New Drug Application For IMM-BCP-01 For The Treatment Of COVID-19 - Benzinga
benzinga.com - December 1 at 7:22 AM
finance.yahoo.com logoImmunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant - Yahoo Finance
finance.yahoo.com - December 1 at 7:22 AM
finance.yahoo.com logoImmunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant
finance.yahoo.com - December 1 at 7:22 AM
finance.yahoo.com logoImmunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19 - Yahoo Finance
finance.yahoo.com - November 30 at 11:20 AM
businesswire.com logoImmunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19 - Business Wire
businesswire.com - November 29 at 7:43 AM
finance.yahoo.com logoImmunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19
finance.yahoo.com - November 29 at 7:43 AM
streetinsider.com logo22nd Century Group (XXII) Announces CFO Transition - StreetInsider.com
streetinsider.com - November 19 at 8:45 AM
businesswire.com logoImmunome Reports Third Quarter 2021 Financial Results - Business Wire
businesswire.com - November 16 at 9:14 AM
finance.yahoo.com logoImmunome Reports Third Quarter 2021 Financial Results - Yahoo Finance
finance.yahoo.com - November 15 at 6:05 PM
finance.yahoo.com logoImmunome to Present at the Stifel Healthcare Conference
finance.yahoo.com - November 10 at 7:40 PM
benzinga.com logoBenzinga's Top Ratings Upgrades, Downgrades For October 29, 2021 - Benzinga
benzinga.com - October 29 at 8:44 PM
seekingalpha.com logoCantor initiates Immunome with an overweight rating on attractive pipeline - Seeking Alpha
seekingalpha.com - October 29 at 8:44 PM
finance.yahoo.com logoImmunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis - Yahoo Finance
finance.yahoo.com - October 20 at 10:34 AM
finance.yahoo.com logoImmunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis
finance.yahoo.com - October 20 at 10:34 AM
bizjournals.com logoLIMR develops the first rapid test to detect the Delta variant in Covid-19 patients - Philadelphia Business Journal - Philadelphia Business Journal
bizjournals.com - October 18 at 5:41 PM
nasdaq.com logoDo Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares? - Nasdaq
nasdaq.com - October 18 at 12:40 PM
finance.yahoo.com logoDo Insiders Own Lots Of Shares In Immunome, Inc. (NASDAQ:IMNM)?
finance.yahoo.com - October 18 at 12:40 PM
finance.yahoo.com logoImmunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Yahoo Finance
finance.yahoo.com - October 7 at 9:38 AM
finance.yahoo.com logoImmunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
finance.yahoo.com - October 7 at 9:38 AM
finance.yahoo.com logoImmunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Yahoo Finance
finance.yahoo.com - September 30 at 8:35 PM
finance.yahoo.com logoImmunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
finance.yahoo.com - September 30 at 8:35 PM
finance.yahoo.com logoImmunome to Present at the Cantor Global Healthcare Conference
finance.yahoo.com - September 22 at 7:54 PM
finance.yahoo.com logoImmunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
finance.yahoo.com - September 15 at 6:41 PM
investors.com logoStocks Showing Market Leadership: Immunome Inc Earns 91 RS Rating - Investor's Business Daily
investors.com - September 15 at 1:40 PM
investors.com logoStock Upgrades: Immunome Inc Shows Rising Relative Strength - Investor's Business Daily
investors.com - September 14 at 4:28 PM
finance.yahoo.com logoImmunome Insider Trades $830.45 Thousand In Company Stock
finance.yahoo.com - September 13 at 6:24 PM
investors.com logoStocks Generating Improved Relative Strength: Immunome Inc - Investor's Business Daily
investors.com - September 13 at 1:23 PM
benzinga.com logoImmunome Insider Trades $830.45 Thousand In Company Stock - Benzinga
benzinga.com - September 13 at 1:23 PM
finance.yahoo.com logo72 Biggest Movers From Yesterday - Yahoo Finance
finance.yahoo.com - September 8 at 8:39 AM
finance.yahoo.com logoImmunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing - Yahoo Finance
finance.yahoo.com - September 7 at 8:00 AM
finance.yahoo.com logoImmunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing
finance.yahoo.com - September 7 at 8:00 AM
businesswire.com logoImmunome Reports Second Quarter 2021 Financial Results - Business Wire
businesswire.com - August 21 at 9:57 PM
finance.yahoo.com logofuboTV (NYSE:FUBO) Can Afford Driving Growth at This Pace - Yahoo Finance
finance.yahoo.com - August 20 at 8:06 AM
Get Immunome News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.